IBT vs. TMPL, TRY, JPE, OCI, BBGI, ICGT, APAX, JEO, RICA, and APEO
Should you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include Temple Bar (TMPL), TR Property Investment Trust (TRY), JPMorgan Elect plc - Managed Growth (JPE), Oakley Capital Investments (OCI), BBGI Global Infrastructure (BBGI), ICG Enterprise Trust (ICGT), Apax Global Alpha (APAX), European Opportunities Trust (JEO), Ruffer Investment (RICA), and abrdn Private Equity Opportunities (APEO). These companies are all part of the "asset management" industry.
International Biotechnology vs. Its Competitors
Temple Bar (LON:TMPL) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.
Temple Bar has a net margin of 98.26% compared to International Biotechnology's net margin of 90.66%. Temple Bar's return on equity of 20.62% beat International Biotechnology's return on equity.
Temple Bar pays an annual dividend of GBX 0.13 per share and has a dividend yield of 0.0%. International Biotechnology pays an annual dividend of GBX 0.30 per share and has a dividend yield of 0.0%. Temple Bar pays out 21.7% of its earnings in the form of a dividend. International Biotechnology pays out 62.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
10.7% of Temple Bar shares are owned by institutional investors. Comparatively, 7.9% of International Biotechnology shares are owned by institutional investors. 0.2% of Temple Bar shares are owned by company insiders. Comparatively, 1.0% of International Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Temple Bar had 3 more articles in the media than International Biotechnology. MarketBeat recorded 4 mentions for Temple Bar and 1 mentions for International Biotechnology. Temple Bar's average media sentiment score of 0.96 beat International Biotechnology's score of 0.00 indicating that Temple Bar is being referred to more favorably in the media.
Temple Bar has higher revenue and earnings than International Biotechnology. Temple Bar is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks.
Temple Bar has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, International Biotechnology has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.
Summary
Temple Bar beats International Biotechnology on 11 of the 15 factors compared between the two stocks.
Get International Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
International Biotechnology Competitors List
Related Companies and Tools
This page (LON:IBT) was last updated on 10/14/2025 by MarketBeat.com Staff
